Michael Greeley, MBA
Michael Greeley, MBA, is a General Partner at Flybridge Capital Partners whose principle investment focus area is the application of "Big Data" platforms across a number of industry verticals. Additionally, Michael is excited about the convergence of healthcare and information technologies, as well as robotics and human-machine interface technologies. Michael currently represents the firm on the boards of BlueTarp Financial, PolyRemedy, Predictive Biosciences, SpringLeaf Therapeutics, T2 Biosystems, TARIS Biomedical, and VidSys and led the firm’s investment in lighterliving, MagenBioSciencesMicroCHIPs, and Protein Forest. Previously, Michael held positions with Polaris Venture Partners, GCC Investments, Wasserstein Perella& Co., Morgan Stanley & Co. and Credit Suisse First Boston. Michael currently serves on the board of the National Venture Capital Association, as Chair of the Entrepreneurship Committee of the Massachusetts Information Collaborative, as co-Founder of the 12x12 program, on the board of the New England Investors’ Committee of Capital Innovation, and was recently appointed a Venture Capital Consultant for the Defense Venture Catalyst Initiative (DeVenCI), an initiative for the Department of Defense. He also serves on the investment committee of the Partners Innovation Fund, is a member of the Executive Business Advisory Council for Mass General Hospital for Children, and a trustee and on the investment committee of the Massachusetts Eye and Ear Infirmary. He previously served as Chairman and President of the New England Venture Capital Association. Michael received a BA with honors in Chemistry from Williams College and an MBA from Harvard Business School.